MINI FUTURE OPTIONSSCHEIN - BOSTON SCIENTIFIC | Real-time Bid/Ask 08:55:17 2024-06-12 EDT | ||
| 2.9 EUR / 2.95 EUR | -1.85% |
|
| Current month | -5.70% | ||
| 1 month | -9.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-12 | 2.92 | -2.01% |
| 24-06-11 | 2.98 | +1.36% |
| 24-06-10 | 2.94 | 0.00% |
| 24-06-07 | 2.94 | -3.29% |
| 24-06-06 | 3.04 | -0.65% |
Delayed Quote Börse Stuttgart
Last update June 12, 2024 at 05:19 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK3LR1 |
| ISIN | DE000JK3LR16 |
| Date issued | 2024-02-09 |
| Strike | 109 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.11 € |
|---|---|
| Lowest since issue | 2.9 € |
| Spread | 0.05 € |
| Spread % | 1.69% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
77.15
USD
Average target price
82.26
USD
Spread / Average Target
+6.62%
- Stock Market
- Certificates
- Certificat
